ZMYM6 is a zinc finger protein involved in cell morphology and cytoskeletal organization regulation. While its precise molecular mechanism remains incompletely characterized, ZMYM6 contains DNA-binding and protein-binding domains localized to the nucleoplasm, suggesting roles in transcriptional regulation and protein interactions. ZMYM6 has emerged as a candidate gene in multiple cancer contexts. In breast cancer, ZMYM6 was identified as part of a concurrent copy number variation and differential gene expression signature associated with clinical outcomes; a 16-gene risk model incorporating ZMYM6 demonstrated significant prognostic value in Han Chinese breast cancer patients, with higher risk scores in patients experiencing recurrence, metastasis, or mortality (P<0.001) 1. In cervical cancer pathogenesis, HPV E7 oncoprotein-mediated downregulation of ZMYM6 expression was observed through promoter hypermethylation, suggesting ZMYM6 involvement in host immune response and cell proliferation pathways suppressed during viral carcinogenesis 2. In cardiac disease, in silico analysis identified ZMYM6 as a miR-483-5p target gene implicated in fibrosis pathways in coronary artery disease and acute myocardial infarction 3. Additionally, ZMYM6 expression changes following gemcitabine exposure were noted in bladder cancer models, indicating involvement in cytoskeletal responses to chemotherapy 4. These findings suggest ZMYM6 functions as a regulator of cellular responses in cancer and cardiovascular disease, though further functional studies are needed to clarify its precise molecular mechanisms.